Trial Profile
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Tebentafusp (Primary) ; Dacarbazine; Ipilimumab; Pembrolizumab
- Indications Uveal melanoma
- Focus Registrational; Therapeutic Use
- Acronyms ATOM
- Sponsors Immunocore
- 05 Jan 2024 According to the Immunocore media release, in 2023, the Company signed an agreement for a European Organisation for Research and Treatment of Cancer (EORTC)-sponsored trial to study KIMMTRAK as adjuvant therapy for uveal (or ocular) melanoma (ATOM). The Company anticipates that the EORTC will randomize the first patient in the second half of 2024.
- 02 Dec 2023 Results comparing overall survival on tebentafusp or pembrolizumab (IMCgp100-202) to nivolumab plus ipilimumab (GEM1402) in untreated mUM using propensity scoring methods, published in the Annals of Oncology.
- 24 Oct 2023 Results assessing 3-yr updated analyses presented at the 48th European Society for Medical Oncology Congress.